Enterprise Value
1.366B
Cash
1.191B
Avg Qtr Burn
-75.42M
Short % of Float
7.69%
Insider Ownership
14.63%
Institutional Own.
80.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DNL343 (eIF2B Activator) Details Amyotrophic lateral sclerosis | Phase 2/3 Data readout | |
DNL310 (ETV:IDS) Details Hunter syndrome MPS II | Phase 2/3 Data readout | |
BIIB122/DNL151 (LRRK2 Inhibitor) Details Parkinson's disease | Phase 2b Data readout | |
DNL758 (CNS-penetrant RIPK1 inhibitor) Details Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis | Phase 2 Data readout | |
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Multiple sclerosis | Phase 2 Data readout | |
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Amyotrophic lateral sclerosis | Phase 2 Data readout | |
TAK-594/DNL593 (PTV:PGRN) Details Frontotemporal dementia with GRN mutations | Phase 1/2 Data readout | |
DNL126 (ETV:SGSH) Details Sanfilippo Syndrome | Phase 1/2 Initiation |